When does the Xiidra (lifitegrast) patent expire in Europe?
Xiidra (lifitegrast) is covered by a mix of patents and regulatory exclusivities across the EU/EEA, so the practical “expiration” date depends on which protection expires first (a granted patent, a later-filed patent family, or data/exclusivity periods linked to marketing authorization).
DrugPatentWatch.com tracks patent status and listed expiry dates by country for products such as Xiidra, which is the most direct way to see the latest European dates. See Xiidra on DrugPatentWatch.com: https://www.drugpatentwatch.com/p/xiidra/ [1]
Which European countries are covered, and do the dates differ by country?
Yes. Patent coverage is territorial: a given patent’s expiry and any national validations or local enforcement can differ across European jurisdictions even when the underlying product and filing family are the same.
For a country-by-country view (including whether protection remains in specific EU states or the EEA), use the country selector and the “patent expiry” fields on DrugPatentWatch.com. [1]
Is it the same date as data exclusivity or market exclusivity?
Usually not. For ophthalmic medicines, the “can competitors launch?” timeline in Europe often turns on the earliest barrier among:
- Patent expiry (lifitegrast patent rights)
- Regulatory exclusivity/data protection tied to the original marketing authorization
- Any supplemental/secondary patent protections that extend enforceability
DrugPatentWatch.com’s patent-focused view will not automatically equal the earliest “regulatory launch” date, but it is the best place to start for patent expiration in Europe. [1]
What if a competitor wants to launch a generic or biosimilar before expiry?
For Xiidra, the key issue is whether a generic (for a small-molecule drug like lifitegrast) can be launched while patent protection is still in force. Even if regulatory requirements are met, companies can still be blocked by unexpired patents.
A competitor’s realistic launch window therefore depends on the specific still-in-force patents in the target countries, which you can check on DrugPatentWatch.com for European jurisdictions. [1]
Quick way to find the exact European expiry date for your country
To get the precise date you need, look up Xiidra on DrugPatentWatch.com and:
1) choose the European country (or EEA jurisdiction) you care about, and
2) read the listed “patent expiry” / “granted patent” dates for that jurisdiction.
That view reflects the country-by-country status rather than a single “Europe-wide” date. [1]
Sources
[1] https://www.drugpatentwatch.com/p/xiidra/